Real-time Estimate
Cboe BZX
20:05:14 13/05/2024 BST
|
5-day change
|
1st Jan Change
|
4.805
USD
|
+3.33%
|
|
+8.05%
|
+85.06%
|
Fiscal Period: December |
2019
|
2020
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
70.45
|
282.7
|
1,437
|
2,608
|
-
|
-
|
Enterprise Value (EV)
1 |
70.45
|
282.7
|
1,437
|
2,608
|
2,608
|
2,608
|
P/E ratio
|
-9.28
x
|
-
|
-2.62
x
|
-
|
-
|
-
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.47
x
|
19.4
x
|
-
|
-
|
-
|
263
x
|
EV / Revenue
|
4.47
x
|
19.4
x
|
-
|
-
|
-
|
263
x
|
EV / EBITDA
|
-
|
-
|
-
|
-18.7
x
|
-16.4
x
|
-15
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
335,890
|
82,260
|
700,843
|
701,980
|
-
|
-
|
Reference price
2 |
1.207
|
3.437
|
2.050
|
3.716
|
3.716
|
3.716
|
Announcement Date
|
30/04/20
|
17/03/21
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
15.75
|
14.54
|
-
|
-
|
-
|
9.927
|
EBITDA
1 |
-
|
-
|
-
|
-139.5
|
-158.8
|
-174.1
|
EBIT
1 |
-25.33
|
-38.35
|
-
|
-144.9
|
-175.4
|
-218.3
|
Operating Margin
|
-160.88%
|
-263.7%
|
-
|
-
|
-
|
-2,199.41%
|
Earnings before Tax (EBT)
|
-25.56
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-22.03
|
-
|
-486.2
|
-
|
-
|
-
|
Net margin
|
-139.92%
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-0.1300
|
-
|
-0.7828
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
30/04/20
|
17/03/21
|
20/02/24
|
-
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
1 |
-
|
-35.59
|
-35.16
|
-34.82
|
-
|
-
|
EBIT
1 |
-33.85
|
-36.24
|
-37.21
|
-37.43
|
-41.62
|
-44.02
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
|
-
|
-
|
-
|
-
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/05/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-155%
|
-100%
|
-135%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
-
|
-
|
-
|
0.08
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
0.8%
|
Announcement Date
|
30/04/20
|
17/03/21
|
20/02/24
|
-
|
-
|
-
|
Last Close Price
3.716
GBP Average target price
5.994
GBP Spread / Average Target +61.30% Consensus |
1st Jan change
|
Capi.
|
---|
| +85.06% | 3.26B | | +5.23% | 109B | | +11.32% | 105B | | -0.38% | 22.25B | | -11.97% | 22.09B | | -7.66% | 18.68B | | -36.52% | 17.58B | | -10.09% | 16.85B | | +3.16% | 13.76B | | +36.45% | 12.46B |
Bio Therapeutic Drugs
|